Verrills Paul, Sinclair Chantelle, Barnard Adele
Metro Pain Group.
Monash Clinical Research, Monash House, Clayton, Victoria, Australia.
J Pain Res. 2016 Jul 1;9:481-92. doi: 10.2147/JPR.S108884. eCollection 2016.
Spinal cord stimulation (SCS) applications and technologies are fast advancing. New SCS technologies are being used increasingly in the clinical environment, but often there is a lag period between the clinical application and the publishing of high-quality evidence on safety and efficacy. Recent developments will undoubtedly expand the applicability of SCS, allowing more effective and individualized treatment for patients, and may have the potential to salvage patients who have previously failed neuromodulation. Already, high-level evidence exists for the safety, efficacy, and cost-effectiveness (Level I-II) of traditional SCS therapies in the treatment of chronic refractory low back with predominant limb pain (regardless of surgical history). More than half of all patients with chronic painful conditions experience sustained and significant levels of pain reduction following SCS treatment. Although only limited evidence exists for burst stimulation, there is now Level I evidence for both dorsal root ganglion SCS and high-frequency SCS that demonstrates compelling results compared with traditional therapies. The body of evidence built on traditional SCS research may be redundant, with newer iterations of SCS therapies such as dorsal root ganglion SCS, high-frequency SCS, and burst SCS. A number of variables have been identified that can affect SCS efficacy: implanter experience, appropriate patient selection, etiologies of patient pain, existence of comorbidities, including psychiatric illness, smoking status, and delay to SCS implant following pain onset. Overall, scientific literature demonstrates SCS to be a safe, effective, and drug-free treatment option for many chronic pain etiologies.
脊髓刺激(SCS)的应用和技术正在迅速发展。新的SCS技术在临床环境中的使用越来越多,但临床应用与高质量的安全性和有效性证据发表之间往往存在滞后。最近的进展无疑将扩大SCS的适用性,为患者提供更有效和个性化的治疗,并可能有潜力挽救先前神经调节治疗失败的患者。传统SCS疗法在治疗以肢体疼痛为主的慢性难治性腰痛(无论手术史如何)方面的安全性、有效性和成本效益(I-II级)已有高级别证据。超过一半的慢性疼痛患者在接受SCS治疗后疼痛得到持续且显著的减轻。尽管关于爆发式刺激的证据有限,但现在有I级证据表明背根神经节SCS和高频SCS与传统疗法相比都有令人信服的结果。基于传统SCS研究建立的证据体系可能与SCS疗法的更新迭代(如背根神经节SCS、高频SCS和爆发式SCS)存在冗余。已经确定了一些可能影响SCS疗效的变量:植入者经验、合适的患者选择、患者疼痛的病因、合并症的存在(包括精神疾病)、吸烟状况以及疼痛发作后至SCS植入的延迟时间。总体而言,科学文献表明SCS是许多慢性疼痛病因的一种安全、有效且无药物的治疗选择。